This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TPM2 / Tropomyosin beta chain · IHC design guide
Design Immunohistochemistry for TPM2
Use muscle tissues with high TPM2 staining as positive controls (HPA tissue IHC). This guide covers consistent fixation and chromogenic paraffin-section IHC, with attention to possible antibody cross-reactivity (standard IHC practice; HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
TPM2 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic F-actin association expected; IHC site unverified (UniProt) | |
| Staining pattern | High in cardiac, skeletal and smooth muscle cells; site unreported (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet A03082-1) | |
| Positive control | Heart muscle+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep paraffin-section fixation consistent across samples. (standard IHC practice; not target-specific) | |
| Caveat | Antibody may detect proteins from other genes (HPA tissue IHC) | |
| Regulation | Breast cancer-associated expression (UniProt) | |
| Isoform / epitope | 3 isoforms; check cytoplasmic epitope coverage (UniProt) |
Section 1
Recommended TPM2 IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by published TPM2 staining details from four PMC articles.
| Sample | Paraffin-embedded human colorectal adenocarcinoma tissue; fixative not specified (datasheet A03082-1) |
| Fixation | Image fixative and duration unreported (datasheet A03082-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet A03082-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A03082-1) |
| Primary antibody | Rabbit anti-TPM2, 2-5 µg/ml (datasheet A03082-1) |
| Primary incubation | Overnight at 4 °C (datasheet A03082-1) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet A03082-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | TPM2-positive staining in cardiomyocytes of heart muscle (HPA tissue IHC: High). HPA tissue profile: Expression in several tissues, most abundant in skeletal, heart and smooth muscle. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated EDTA pH 8.0 retrieval (datasheet: EDTA pH 8.0 HIER); the cited excerpts do not specify a retrieval buffer.
Section 2
What Is the Expected TPM2 Staining Pattern?
TPM2 should appear in the cytoplasm along actin-associated structures, especially in cardiomyocytes, skeletal myocytes, and smooth muscle cells (UniProt P07951: cytoskeleton and F-actin stress fibers; HPA: High in these cells). It has no transmembrane segment (UniProt P07951: topology). HPA rates its tissue IHC staining Approved but reports low agreement with RNA data and cautions that the antibodies may detect products of more than one gene (HPA: reliability description).
| Strong cytoplasmic staining in heart, skeletal, or smooth muscle, with little nuclear staining. | This fits the expected location and the strongest reported tissue patterns (UniProt P07951: cytoskeleton; HPA: High in cardiomyocytes, myocytes, and smooth muscle cells). Judge the pattern within identifiable cells; HPA's multi-gene caution limits how confidently staining can be assigned to TPM2 alone (HPA: reliability description). |
| Predominantly nuclear or crisp cell-surface staining, without a convincing cytoplasmic component. | Treat this as a compartment mismatch requiring investigation, since TPM2 associates with F-actin stress fibers and has no transmembrane segment (UniProt P07951: subcellular location and topology). Review morphology and the detection controls before scoring it as specific staining (general IHC practice). |
| Strong staining in an unexpected cell population, especially where HPA reports no detection. | For example, adipocytes and lymph-node non-germinal center cells are reported as Not detected (HPA: tissue IHC). Unexpected signal may reflect cross-reactivity or endogenous detection activity (general IHC practice); HPA also cautions that the antibodies may recognize products of more than one gene (HPA: reliability description). |
| Diffuse color across cells and surrounding tissue, with poor separation of compartments. | A widespread haze is difficult to interpret as TPM2 because the expected location is cytoskeletal (UniProt P07951: subcellular location). Check background with a primary-antibody omission control, then review blocking, washing, antibody concentration, and chromogen development as general IHC variables (general IHC practice). |
| No staining in a section expected to provide a strong positive control. | Heart, skeletal muscle, and smooth muscle contain cell populations scored High by HPA (HPA: tissue IHC). A blank result there calls for a check of tissue preservation, staining reagents, detection, and the catalog antibody's validated IHC-P conditions (general IHC practice); it does not by itself establish TPM2 absence. |
💡Expected TPM2 appearanceA convincing positive shows strong cytoplasmic, actin-associated staining in cardiomyocytes, skeletal myocytes, or smooth muscle cells (HPA: High; UniProt P07951: F-actin stress fibers); isolated nuclear, membrane-only, or diffuse tissue-wide color is suspect (UniProt P07951: location and topology; general IHC practice).
| Tissue and cell selection | Use heart, skeletal muscle, or smooth muscle for a high-signal reference (HPA: High). Leydig cells are also scored High, while breast glandular cells are scored Medium (HPA: tissue IHC). Score the named cell population rather than treating every cell in a tissue as equally positive (HPA: cell-level entries). |
| Specificity of the observed signal | HPA classifies tissue staining as Approved but reports low agreement with RNA and cautions that antibodies may detect products of more than one gene (HPA: reliability description). Its listed IHC antibodies, HPA047089 and HPA053624, are each Approved; neither is listed as Enhanced (HPA: antibody validation). |
| Isoforms and intracellular location | UniProt lists three TPM2 isoforms and describes an F-actin-associated cytoskeletal protein without a transmembrane segment (UniProt P07951: isoforms, location, topology). Isoform recognition cannot be inferred without antibody epitope information; avoid assigning a distinct staining pattern to any isoform from these sources alone. |
| Breast-tissue interpretation | UniProt reports TPM2 present in primary breast cancer tissue and absent from normal breast tissue, while HPA scores normal breast glandular cells Medium by IHC (UniProt P07951: tissue specificity; HPA: breast). Treat this source disagreement and HPA's multi-gene caution as limits on using breast staining alone to establish TPM2 specificity. |
| Situation | Likely cause | Next action |
|---|---|---|
| Known-positive muscle is blank or unexpectedly weak. | A control that HPA scores High has failed to show the expected signal (HPA: heart, skeletal muscle, smooth muscle). | Confirm the named cells are present; check the catalog antibody's IHC-P instructions, retrieval and dilution settings, reagent activity, and detection controls (general IHC practice). No TPM2-specific retrieval condition is supplied here. |
| Apparent nuclear or membrane-only staining dominates. | The pattern conflicts with TPM2's cytoskeletal location and lack of a transmembrane segment (UniProt P07951: location and topology). | Compare with a known-positive muscle section and an omission control; reassess cell boundaries and background before calling the compartment positive (HPA: High in muscle; general IHC practice). |
| Negative-reference cells show strong staining. | Adipocytes and lymph-node non-germinal center cells are reported Not detected; cross-reactivity or endogenous detection activity is possible (HPA: tissue IHC; general IHC practice). | Run a primary-antibody omission control, check endogenous detection activity, and interpret any residual signal cautiously given HPA's multi-gene warning (general IHC practice; HPA: reliability description). |
| Diffuse brown background obscures cell-level scoring. | General IHC causes include insufficient blocking or washing, excessive antibody concentration, or prolonged chromogen development (general IHC practice). | Use an omission control to locate background, then optimize those workflow variables against a known-positive muscle control (general IHC practice; HPA: High in muscle). |
| Breast staining appears inconsistent across the reference sources. | HPA reports Medium staining in normal breast glandular cells, whereas UniProt reports absence from normal breast tissue (HPA: breast; UniProt P07951: tissue specificity). | Record the observed cells and staining intensity, compare with muscle controls, and avoid using breast staining as sole evidence of specificity (HPA: reliability caution; general IHC practice). |
| IF/ICC: what pattern can be expected? | An actin-associated cytoplasmic pattern is plausible from UniProt, but HPA supplies no main subcellular location or ICC-IF images for this entry (UniProt P07951: F-actin stress fibers; HPA: subcellular record). | Treat that pattern as a hypothesis to validate with suitable IF/ICC controls; the HPA tissue IHC result alone does not establish an IF/ICC pattern (HPA: subcellular record; general IF practice). |
Experiment evidence
IHC & IF images showing TPM2 staining
A03082-1 · IHCIHC analysis of Tropomyosin 2/TPM2 using anti-Tropomyosin 2/TPM2 antibody (A03082-1). Tropomyosin 2/TPM2 was detected in a paraffin-embedded
A03082-1 · IHCIHC analysis of Tropomyosin 2/TPM2 using anti-Tropomyosin 2/TPM2 antibody (A03082-1). Tropomyosin 2/TPM2 was detected in a paraffin-embedded
A03082-1 · IFIF analysis of Tropomyosin 2/TPM2 using anti-Tropomyosin 2/TPM2 antibody (A03082-1). Tropomyosin 2/TPM2 was detected in a paraffin-embedded
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000198467-TPM2/tissue/cerebral+cortex#imid_15308450
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000198467-TPM2/tissue/colon#imid_15308392
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000198467-TPM2/tissue/liver#imid_15308385
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000198467-TPM2/tissue/kidney#imid_15308394
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for TPM2 IHC & IF
🧪Run skeletal muscle first; myocytes should stain strongly (HPA: High in skeletal muscle myocytes). Use adipose tissue as the negative, where adipocytes are not detected; any interstitial adipocytes on the skeletal muscle slide can serve as internal negative cells (HPA: Not detected in adipocytes).
Positive control tissue: Heart muscle (Cardiomyocytes, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for TPM2; derive a cell-line control from the positive tissue's cell type (Cardiomyocytes) and confirm it by RNA or western blot first.
Technical controls: Include a no-primary, secondary-only control and a rabbit IgG control matched to the primary antibody’s clonality and isotype (caption: rabbit primary; standard IHC practice). Test specificity with TPM2-knockout material or cognate-peptide blocking when available; quench endogenous peroxidase in skeletal muscle before HRP/DAB detection (caption: HRP/DAB; standard IHC practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported, and the exact A03082-1 paraffin-section caption does not state a fixative (caption: fixative not stated). The caption demonstrates heat retrieval in EDTA at pH 8.0, but does not establish whether retrieval is required or whether other conditions work (caption: EDTA heat retrieval). Frozen-section IF is not established as easier by the supplied evidence; endogenous peroxidase in muscle can complicate HRP/DAB interpretation unless quenched (HPA: no ICC-IF images listed; standard IHC practice).
HPA tissue IHC evidence for TPM2
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data. Caution, targets protein from more than one gene. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Heart muscle | Cardiomyocytes | High | Protein (IHC) | HPA → |
| Skeletal muscle | Myocytes | High | Protein (IHC) | HPA → |
| Smooth muscle | Smooth muscle cells | High | Protein (IHC) | HPA → |
| Testis | Leydig cells | High | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Lymph node | Non-germinal center cells | Not detected | Protein (IHC) | HPA → |
| Parathyroid gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Small intestine | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Spleen | Cells in red pulp | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced TPM2 IHC Tips
Troubleshoot TPM2 staining in paraffin sections by checking retrieval, controls, cellular localisation and scoring before interpreting chromogenic signal.
Which retrieval conditions should I use when TPM2 staining is weak in paraffin sections?
Start with heat-mediated retrieval in EDTA at pH 8.0 for TPM2 paraffin IHC (datasheet A03082-1). The selected tissue image used this retrieval before 2 μg/ml primary antibody overnight at 4°C (caption A03082-1). Keep heating and cooling conditions consistent, and compare a muscle-rich positive section with a no-primary control (standard IHC practice; HPA: high in skeletal-muscle myocytes). If staining remains weak, adjust retrieval duration on serial sections before testing another buffer, while checking that morphology remains intact (standard IHC practice). Favor clear cytoplasmic staining over diffuse color, consistent with TPM2 association with F-actin stress fibers (UniProt P07951 localisation).
Could fixation explain weak or uneven TPM2 staining?
Target-specific fixation sensitivity is unknown: the selected paraffin tissue caption does not state a fixative (caption A03082-1). Record fixation method and duration for each specimen, and compare sections processed under matched conditions before attributing intensity differences to TPM2 biology (standard IHC practice). Include a known positive section in the same run to distinguish a specimen problem from an assay problem (standard IHC practice; HPA: high in heart-muscle cardiomyocytes). If morphology or staining varies across a section, inspect processing and section thickness alongside fixation records (standard IHC practice). Do not infer a TPM2-specific fixation effect from its cytoskeletal location or annotated modifications (UniProt P07951 localisation and modified residues).
Where should I expect TPM2 signal, and how should I assess an unexpected pattern?
Expect predominantly cytoplasmic staining with a filament-associated pattern, because TPM2 associates with F-actin stress fibers (UniProt P07951 localisation). It has no transmembrane segment or signal peptide, so isolated membrane outlining or secretory-pattern staining needs scrutiny (UniProt P07951 topology and processing). Examine cellular morphology and a matched no-primary control before treating diffuse nuclear or extracellular color as specific (standard IHC practice; UniProt P07951 localisation). Muscle-rich sections offer useful positive context: cardiomyocytes, skeletal myocytes and smooth-muscle cells show high tissue-IHC staining (HPA: high in heart, skeletal and smooth muscle). Compare the same compartment across cases under matched retrieval and detection conditions (standard IHC practice).
Can this stain distinguish TPM2 isoforms or exclude staining of other tropomyosins?
Do not assign an isoform from this chromogenic signal alone: TPM2 has 3 annotated isoforms, and the supplied caption gives no epitope map (UniProt P07951 isoforms; caption A03082-1). Check the antibody's epitope documentation against the isoform sequences before making an isoform-specific claim (standard IHC practice). TPM2 can form heterodimers with TPM1, TPM3 or TPM4 chains, but a positive stain does not identify its binding partner (UniProt P07951 subunit). The tissue-IHC resource cautions that its staining may detect protein from more than one gene (HPA: reliability description). Use an independent specificity control when the distinction matters, and report the result as antibody-associated TPM2 staining until resolved (standard IHC practice).
How can I investigate a TPM2 pattern with multiplex immunofluorescence?
Use IF as a separate validation experiment, since the supplied image documents chromogenic paraffin IHC for this antibody (caption A03082-1). Pair TPM2 with a validated marker for the expected cell type, then inspect whether its signal occupies the cytoplasm of the same cells (standard IF practice; UniProt P07951 localisation). Choose spectrally separated fluorophores after checking tissue autofluorescence in unstained sections, and include single-label controls for bleed-through (standard IF practice). Permeabilise as needed to expose the intracellular epitope, because TPM2 is cytoplasmic and has no transmembrane segment (standard IF practice; UniProt P07951 topology and localisation). The supplied HPA subcellular record provides no ICC/IF images to establish an antibody-specific IF pattern (HPA: subcellular record).
How do I reduce diffuse brown background without losing genuine TPM2 signal?
Compare no-primary and positive-control sections before changing the antibody concentration, so detection background is separated from tissue-associated staining (standard IHC practice). The selected image used 10% goat serum blocking, 2 μg/ml primary antibody overnight at 4°C, and DAB detection (caption A03082-1). If diffuse color persists, optimise blocking, washes and primary incubation on matched sections while preserving a visible positive compartment (standard IHC practice). Include an endogenous-peroxidase block for HRP/DAB workflows, and inspect pigment or deposits separately from cellular staining (standard IHC practice). TPM2 is cytoplasmic and filament-associated, so uniform extracellular haze is a poor match to its expected distribution (UniProt P07951 localisation).
What scoring method makes TPM2 IHC results comparable between specimens? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and cytoplasmic compartment before scoring, because TPM2 associates with F-actin stress fibers (UniProt P07951 localisation). Within that population, report the percentage of positive cells and intensity categories, or calculate an H-score as the sum of percentage at each intensity multiplied by its category (standard IHC practice). Use the same threshold, section area and imaging settings across specimens, with a control section in each staining run (standard IHC practice). Normalise cell counts or positive area to the evaluable tissue area, and exclude folds, edges and necrosis from that denominator (standard IHC practice). Report muscle and non-muscle compartments separately when present, because tissue expression varies by cell type (HPA: tissue IHC profile).
How can I distinguish true TPM2 staining from artefact in a complex section?
A credible positive pattern is cellular and cytoplasmic, consistent with TPM2 association with F-actin stress fibers (UniProt P07951 localisation). Check whether strongly stained cells fit the expected compartment: HPA reports high staining in cardiomyocytes, skeletal myocytes and smooth-muscle cells (HPA: tissue IHC). Treat isolated nuclear color, section-edge accentuation, necrotic debris or staining in a no-primary control as possible artefact requiring review (standard IHC practice; UniProt P07951 localisation). In HRP/DAB sections, repeat or check endogenous-peroxidase blocking when brown signal appears unrelated to cellular morphology (standard IHC practice; caption A03082-1: HRP/DAB detection). Interpret unexpected cell-type staining cautiously because the tissue-IHC resource reports low RNA–protein consistency and possible detection of more than one gene (HPA: reliability description).
Boster reagents
Best TPM2 / Tropomyosin beta chain IHC Antibodies
A03082-1 has real IHC and IF images from human paraffin sections (A03082-1 image captions); the catalog lists human, mouse and rat reactivity (catalog reactivity).
Real IHC data
Anti-Tropomyosin 2/TPM2 Antibody ®
Cat # A03082-1
A03082-1 is listed for IHC and IF with human, mouse and rat reactivity (catalog applications and reactivity). Its captions show IHC in human colorectal adenocarcinoma, lung adenocarcinoma, placenta and spleen paraffin sections, and IF in human placenta paraffin sections (A03082-1 image captions).
Which to pick: For tissue IHC, choose A03082-1: its colorectal adenocarcinoma paraffin-section caption documents EDTA retrieval at pH 8.0 and 2 µg/ml primary antibody; the fixative is unreported (A03082-1 IHC caption). For IF, A03082-1 has a human placenta paraffin-section example at 5 μg/ml; no ICC example is shown (A03082-1 IF caption and catalog image captions). For cross-species work, A03082-1 lists mouse and rat reactivity, but the displayed IHC and IF examples are human (catalog reactivity; A03082-1 image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P07951 (TPM2_HUMAN, Tropomyosin beta chain).
- Human Protein Atlas. TPM2 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. TPM2 subcellular location (ICC-IF): Highest expression in BJ [Human fibroblast]: 2194.8 nTPM.
- Human Protein Atlas. TPM2 antibody validation summary (2 antibodies).
- Relevance Analysis of TPM2 and Clinicopathological Characteristics in Breast Cancer. International journal of general medicine 2024 — PMC10788065.
- Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance. Leukemia 2025 — PMC11717704.
- Construction of a prognostic model for colorectal cancer liver metastasis based on single-cell transcriptomics and regulation of the MIF pathway. Frontiers in oncology 2025 — PMC12537406.
- A Novel Gene List Identifies Tumors with a Stromal-Mesenchymal Phenotype and Worse Prognosis in Gastric Cancer. Cancers 2023 — PMC10252086.
- PubMed PMID:3865200 — UniProt-cited evidence.
- PubMed PMID:3368322 — UniProt-cited evidence.
- PubMed PMID:2059197 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for TPM2 (Tropomyosin beta chain). Expected localisation Cytoplasmic F-actin association expected; IHC site unverified (UniProt). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet A03082-1). Validated IHC antibody: A03082-1 at 2-5 µg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Heart muscle (Cardiomyocytes); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human colorectal adenocarcinoma tissue; fixative not specified (datasheet A03082-1); 2. Fixation: Image fixative and duration unreported (datasheet A03082-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet A03082-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A03082-1); 8. Primary antibody: Rabbit anti-TPM2, 2-5 µg/ml (datasheet A03082-1); 9. Primary incubation: Overnight at 4 °C (datasheet A03082-1). Watch for: Fixation: Keep paraffin-section fixation consistent across samples. (standard IHC practice; not target-specific); Caveat: Antibody may detect proteins from other genes (HPA tissue IHC); Isoform / epitope: 3 isoforms ; check cytoplasmic epitope coverage (UniProt); Regulation: Breast cancer-associated expression (UniProt). Evidence: UniProt P07951, HPA tissue IHC · Approved, HPA cell-line RNA · Highest expression in BJ [Human fibroblast]: 2194.8 nTPM, Datasheet A03082-1, PMC10788065, PMC11717704. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/TPM2/immunohistochemistry-ihc-guide.